Molgora S, Baldini MP, Tamanza G, Somigliana E, Saita E
Why the FDA Issued Warnings The FDA determined that companies marketing compounded retatrutide: Sold an unapproved new drug without FDA authorization Misbranded products by providing no adequate directions for safe use Improperly claimed compounding exemptions that do not apply to investigational substances In short, these products are not permitted for compounding or distribution under current federal law
The theoretical cancer concern applies to TB-500 as well, though perhaps to a lesser extent
X., Jung, D
See, it falls under the Research Chemical section, meaning anyone can purchase it under the nomenclature of nor for human use and for research purposes only
Some people with clearly high blood sugar notice nothing unusual, while others notice an odor before they notice any change in color or amount